Tyrphostins--potential antiproliferative agents and novel molecular tools

Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling.

Oncogene·2015

Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling.

Oncogene·2015

Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents.

Oncogene·2010

Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor.

Oncogene·2006

Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase.

Biochemical pharmacology·2006

Stochastic algorithm for kinase homology model construction.

Current medicinal chemistry·2004

Targeting glycolytic enzymes to combat cancer metastasis: Strategies toward clinical translation.

Biochemical pharmacology·2026

Functional and structural interactions of novel acrylamide-based compounds with the α7 nicotinic acetylcholine receptor.

Biochemical pharmacology·2026

Progress of TRAF6 in the pathogenesis of depression: opportunities and challenges from molecular mechanisms to therapeutic targets.

Biochemical pharmacology·2026

A review on tumor-targeting liposomes: Fabrication, mechanism and applications.

Biochemical pharmacology·2026

Non-covalent mTOR inhibition suppresses NLRP3-GSDMD inflammasome-mediated pyroptosis.

Biochemical pharmacology·2026

The MAPK pathway as a pharmacological target to reprogram cancer-associated fibroblasts and disrupt the stromal shield.

Biochemical pharmacology·2026

Structural Modifications of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): New Horizons in Antimicrobial Drug Discovery.

Archiv der Pharmazie·2026

Benzophenone Derivatives as a New Class of Anti-Infectives Against Acanthamoeba spp.

Archiv der Pharmazie·2026

Novel 1H-Indole-3-carboxamide Derivatives as CDK4 Inhibitors for Treating Cancer.

ACS medicinal chemistry letters·2026

Novel Heterocyclic Compounds for Treating HIV Infection.

ACS medicinal chemistry letters·2026

Novel 6,5-Bicyclic Compounds as 5‑HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches.

ACS medicinal chemistry letters·2026

Advancing Next-Generation Psychedelic Therapeutics through Selective 5‑HT2A Activation, Precision Aerosol Delivery, and Optimized 5‑MeO-DMT Treatment Paradigms.

ACS medicinal chemistry letters·2026

Related Experiment Videos

Tyrphostins--potential antiproliferative agents and novel molecular tools

Related Concept Videos

Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling.

Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling.

Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents.

Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor.

Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase.

Stochastic algorithm for kinase homology model construction.

Targeting glycolytic enzymes to combat cancer metastasis: Strategies toward clinical translation.

Functional and structural interactions of novel acrylamide-based compounds with the α7 nicotinic acetylcholine receptor.

Progress of TRAF6 in the pathogenesis of depression: opportunities and challenges from molecular mechanisms to therapeutic targets.

A review on tumor-targeting liposomes: Fabrication, mechanism and applications.

Non-covalent mTOR inhibition suppresses NLRP3-GSDMD inflammasome-mediated pyroptosis.

The MAPK pathway as a pharmacological target to reprogram cancer-associated fibroblasts and disrupt the stromal shield.

Structural Modifications of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): New Horizons in Antimicrobial Drug Discovery.

Benzophenone Derivatives as a New Class of Anti-Infectives Against Acanthamoeba spp.

Novel 1H-Indole-3-carboxamide Derivatives as CDK4 Inhibitors for Treating Cancer.

Novel Heterocyclic Compounds for Treating HIV Infection.

Novel 6,5-Bicyclic Compounds as 5‑HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches.

Advancing Next-Generation Psychedelic Therapeutics through Selective 5‑HT2A Activation, Precision Aerosol Delivery, and Optimized 5‑MeO-DMT Treatment Paradigms.

Related Experiment Videos

Tyrphostins--potential antiproliferative agents and novel molecular tools

Related Concept Videos

Related Articles